Pemphigus
https://www.niams.nih.gov/health-topics/pemphigus
https://www.niams.nih.gov/health-topics/pemphigus
https://www.niams.nih.gov/health-topics/pemphigus
https://www.niams.nih.gov/health-topics/vitiligo
https://www.niams.nih.gov/health-topics/vitiligo
https://www.niams.nih.gov/health-topics/scleroderma
https://www.niams.nih.gov/health-topics/scleroderma
https://www.niams.nih.gov/health-topics/rosacea
https://www.niams.nih.gov/health-topics/rosacea
https://www.niams.nih.gov/health-topics/psoriasis
https://www.niams.nih.gov/health-topics/psoriasis
https://www.niams.nih.gov/health-topics/gout
https://www.niams.nih.gov/health-topics/gout
https://www.niams.nih.gov/health-topics/gout
https://www.niams.nih.gov/labs/rheumatology-training-program
https://www.niams.nih.gov/aad-2019
https://www.niams.nih.gov/health-topics/hidradenitis-suppurativa-hs
https://www.niams.nih.gov/health-topics/hidradenitis-suppurativa-hs
https://www.niams.nih.gov/labs/science-technology/genomic-technology-section
https://www.niams.nih.gov/about/budget/fy2020/congressional-justification
The Clinical Research Operations and Management Branch (CROMB) has responsibility for assessing study risk, implementing data and safety monitoring oversight, tracking enrollment progress, and mitigating study related issues for the complete portfolio of NIAMS funded clinical trials and select human subjects observational studies with some level of risk (60-70 studies currently active in the managed portfolio). Specifically, this responsibility includes: